Lyell Immunopharma, Inc. (LYEL) has 14 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 10 sales totalling $211K. Most recent filing: Sept. 10, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 10, 2026 | Shook David Chief Medical Officer | −$6,350 | 500 | −2% | No | |
|
|
||||||
| Sept. 10, 2026 | Aguirre Jarrad Mattieu Chief Medical Officer | $0 | 47,500 | 0% | No | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 21, 2026 | Seely Lynn President and CEO | −$149,013 | 9,589 | −13% | No | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 21, 2026 | Hill Stephen J. Chief Operating Officer | −$15,369 | 989 | −6% | No | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 21, 2026 | Lee Gary K. Chief Scientific Officer | −$22,642 | 1,457 | −8% | No | |
|
|
||||||
Showing the 5 most recent of 14 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free